Date: 2017-05-08
Type of information: Licensing agreement
Compound: Lipid Nanoparticle (LNP) technologies
Company: Crispr Therapeutics (Switzerland - UK) the Massachusetts Institute of Technology (MIT) (USA - MA)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism:
Disease:
Details:
- • On May 8, 2017, CRISPR Therapeutics announced they have signed an exclusive license with the Massachusetts Institute of Technology (MIT) for a family of Lipid Nanoparticle (LNP) technologies developed in the lab of Dr. Daniel G. Anderson, a scientific founder and advisory board member of CRISPR Therapeutics. “Our laboratory has worked to develop non-viral delivery vectors for nucleic acids, and we are finding that LNP technologies work very well for delivering the CRISPR/Cas9 system. In fact, gene editing applications may be particularly well-suited to LNP delivery given the potential for single dose efficacy. I am excited to see CRISPR-based in vivo therapies moving rapidly toward the clinic,” said Dr. Daniel Anderson.
- Under the terms of the license, CRISPR Therapeutics obtains the exclusive rights to use the LNP technologies in their therapeutic development programs focused on in vivo gene editing applications. MIT receives an upfront technology access fee, milestones, and royalties on licensed products that reach the market.
Financial terms:
Latest news:
Is general: Yes
